We are excited to announce that StratifiCare Inc., developer of the world’s first Severe Dengue prediction test, welcomes Leesa Soulodre on board as our Corporate Strategy Advisor.
Most recently the Managing Partner of RL Expert Group and Innovation Director of Inspirit IoT, Leesa is a serial entrepreneur with over 20 years of experience in cutting edge of innovation, technology and strategy consulting. To date, Leesa has advised more than 400 multinationals and start-ups in 19 sectors across Europe, Asia-Pacific and the Americas, and led companies from Seed to $14B USD into new markets. Her work in strategy, reputation, risk, and technology has enabled companies with
proven strategies, tools and technologies to acquire, protect and support their licenses to operate, mitigate risks and exploit opportunities for accelerated market access and revenue growth. Leesa holds expert industry expertise in deep technology, insurance, fintech, healthcare and pharmaceutical sectors.
StratifiCare is revolutionizing Dengue care with technology. StratifiCare has developed a clinical blood test to predict the risk of Severe Dengue complications accurately – a simple yes/no for hospitalization. This test can reduce the Dengue hospitalization burden by 67%. The growing global Dengue prognostic test market is estimated to be worth US$3.3 billion, with a CAGR of 7%.
“We are really excited to have Leesa on board our team. Leesa’s in-depth experience in innovation, technology and strategy will strongly bolster our efforts to become the leading diagnostic company to empower personalized medicine for tomorrow,” Anthony Chua, co-founder and CEO of StratifiCare, commented.